ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Etoricoxib

Also written as “etoricoxib”, “MK0663, etoricoxib” and “MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days”.

Its studies are mostly in Osteoarthritis · Pain · Low Back Pain · Acute Pain · Dysmenorrhea, led by 7 companies.

Drug pageEtoricoxib: every studyMany companies study it; this page follows only the 34 they lead. All 71 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 25, 200434 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Organonits history only230 open or runningphase 4since Aug 25, 2004Aug 25, 2004none ahead
Laboratorios Silanes S.A. de C.V.its history only61 open or runningphase 3since Jul 13, 2021Jul 13, 2021Dec 31, 2026phase 3 · NCT06863701
Analgesic Solutionsits history only10 open or runningphase 4since Dec 20, 2010Dec 20, 2010none ahead
Dexa Medica Groupits history only10 open or runningno phasesince Jan 30, 2018Jan 30, 2018none ahead
Laboratorios Liomont10 open or runningphase 3since Apr 15, 2026Apr 15, 2026none ahead
Pharmtechnologyits history only10 open or runningphase 1since Mar 31, 2021Mar 31, 2021none ahead
X-pert Medits history only10 open or runningphase 1since Jan 5, 2011Jan 5, 2011none ahead

Also a collaborator on its studies: EPIC Research CRO, PT Equilab International and Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Laboratorios Liomont only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 15, 2026First study: phase 3 study in AgnosiaFirst studyNCT07549386 · 123 enrolled · Mexico

TargetBeta

PTGS2 →read by rule
“Cyclooxygenase-2 inhibitor”ChEMBL 37, by rule

Other programs on PTGS2

ProgramCompanyFurthest phaseStudies
AcetaminophenruleJohnson & Johnsonphase 4136
IbuprofenrulePfizerphase 4113
AspirinruleBayerphase 484
CelecoxibruleViatrisphase 478
MeloxicamruleBoehringer Ingelheimphase 467
dexketoprofenruleMenarini Groupphase 48
SulfasalazineruleBristol-Myers Squibbphase 47
dexibuprofenruleaponia-laboratories-incphase 46
BenzydamineruleAngelini Pharmaphase 44
DipyroneruleHypera Pharmaphase 44
PiroxicamruleTaisho Pharmaceuticalphase 44
FlurbiprofenruleGlaxoSmithKlinephase 312

Studies

The one study Laboratorios Liomont leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07549386Agnosia · Mexico3CompletedMar 27, 2025123

How it is read

Names in the registry

  • “etoricoxib”, 7 entries
  • “Etoricoxib”, 4 entries
  • “MK0663, etoricoxib”, 3 entries
  • “MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days”, 2 entries
  • “Etoricoxib 90 mg”, 2 entries

Codes read as this program: MK0663.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.